Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Coherus BioSciences Q4 2023 Adj EPS $(0.62) Misses $(0.12) Estimate, Sales $91.524M Miss $96.400M Estimate

Author: Benzinga Newsdesk | March 13, 2024 04:03pm
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.12) by 416.67 percent. The company reported quarterly sales of $91.524 million which missed the analyst consensus estimate of $96.400 million by 5.06 percent. This is a 101.81 percent increase over sales of $45.352 million the same period last year.

Posted In: CHRS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist